Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Lithium May Help Radiation Target Cancer, Spare Healthy Tissue

By HospiMedica International staff writers
Posted on 27 May 2009
Investigators have discovered a mechanism that helps clarify how lithium, a drug widely used to treat bipolar mood disorder, also protects the brain from damage that occurs during radiation treatments.

In the May 1, 2009, issue of the Journal of Clinical Investigation, Fen Xia, M.D., Ph.D., and colleagues from Vanderbilt [University]-Ingram Cancer Center (Nashville, TN,USA) demonstrated that lithium promotes DNA repair in healthy cells but not in brain tumor cells. More...
The findings suggest that lithium treatment could offer a way to protect healthy brain tissue from damage that may occur during cranial radiation treatments.

Cranial irradiation is part of standard therapy for both primary and metastatic brain tumors. However, as with all treatment modalities, radiation frequently causes long-term side effects. Specifically, neurologic impairments--including lowered IQ, learning difficulties, and memory loss--have been reported, particularly in children treated for brain cancers. Radiation-induced damage to the healthy cells of the hippocampus, a brain structure crucial for learning and memory, is one likely source of these deficits.

These cognitive impairments have long-lasting effects on the quality of life for survivors, noted Dr. Xia, an assistant professor of radiation oncology and cancer biology. "Because these patients can now survive longer and are being cured, alleviating long-term toxicity is becoming more important,” she said.

Researchers have been looking for agents that could protect healthy brain tissue from radiation-induced damage. Previously, Vanderbilt-Ingram investigators--led by Dennis Hallahan, M.D., chair of radiation oncology and a professor of cancer research--found that lithium treatment protects cultured hippocampal neurons from radiation-induced cell death and improves cognitive performance in irradiated mice.

But how lithium protects against radiation-induced damage is not clear. Radiation kills tumor cells by damaging their DNA, but it can also attack the DNA of healthy cells. One of the most serious types of DNA damage is the chromosomal double-stranded break (DSB), in which both strands of the double helix are severed. Even a single unrepaired DSB can be lethal to a cell. Fortunately, the body has several different ways to repair DNA damage.

Dr. Xia, whose lab studies the mechanisms of DNA repair in normal cells and tumor cells, suspected that lithium might affect how DNA is repaired following radiation-induced damage. Working with Eddy Yang, M.D., Ph.D., a resident in the radiation oncology department and postdoctoral research fellow Hong Wang, M.D., Ph.D., Dr. Xia and colleagues examined DNA repair in lithium-treated mouse hippocampal neurons exposed to radiation.

The investigators discovered that lithium did not prevent the generation of DSBs but promoted a specific kind of DNA repair--called nonhomologous end-joining (NHEJ) repair--which is the predominant repair mechanism used by normal neurons. Dr. Xia and colleagues showed biochemical and genetic evidence that radiation-induced DSBs were repaired with greater efficiency in lithium-treated cells via the NHEJ pathway.

However, none of these effects were observed in malignant glioma (brain tumor) cells, presumably because cancer cells typically utilize a different DNA repair mechanism, according to Dr. Xia. The researchers validated these findings in mice treated with cranial radiation. The results suggest that lithium protects healthy hippocampal neurons by promoting NHEJ-mediated DNA repair--but that lithium offers no protective effect in the brain tumor cells tested.

Since some tumors are resistant to radiation, Dr. Xia hopes that lithium treatment could provide a way to increase the radiation dose to levels that will kill the tumor cells while protecting healthy brain tissue. The team is initiating an investigation of the safety and feasibility of lithium treatment in patients with low-grade glioma or brain metastases from small cell lung cancer.

"Right now, the problem is that we cannot kill the tumor completely because normal tissue toxicity limits the dose,” Dr. Xia said. "So if we can protect normal tissue, we can hopefully give a higher dose to the tumor.”

Related Links:

Vanderbilt-Ingram Cancer Center



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
LED Surgical Lamp
ACEMST35/57
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.